Patent Application
20230204584
The present invention can be included in the medical field. Particularly, the present invention refers to an in vitro method for screening general population for colorectal cancer and/or pre-cancerous stage thereof.
Colorectal cancer (CRC) (also known as colon cancer, rectal cancer, or bowel cancer) is the development of cancer in the colon or rectum (parts of the large intestine). The vast majority of colorectal cancers is adenocarcinomas. This is because the colon has numerous glands within the tissue. When these glands undergo several changes at the genetic level, they proceed in a predictable manner as they move from benign to an invasive, malignant colon cancer. The adenomas of the colon, particularly advanced colorectal adenoma (AA), are a benign version of the malignant adenocarcinomas but still with malignant potential if not removed (they are usually removed because of their tendency to become malignant and to lead to colon cancer).
Screening is an effective way for preventing and decreasing deaths from colorectal cancer. The best known and most frequently used screening test for colorectal cancer is called Fecal Immunochemical Test (FIT). FIT detects blood in the stool samples which can be a sign of pre-cancer or cancer. If abnormal results are obtained, usually a colonoscopy is recommended which allows the physician to look at the inside of the colon and rectum to make a diagnosis. During colonoscopy, small polyps may be removed if found. If a large polyp or tumor is found, a biopsy may be performed to check if it is cancerous. The gastroenterologist uses a colonoscopy to find and remove these adenomas and polyps to prevent them from continuing to acquire genetic changes that will lead to an invasive adenocarcinoma.
Although, as explained above, FIT is nowadays used for screening colorectal cancer, it is important to note that FIT offers a low sensitivity for AA (around 20-30% depending on literature) which means that most of said kind of patients can be wrongly classified as not having the disease. Consequently, FIT is not able to identify adenomas due to its low sensitivity. Moreover, since FIT uses stool samples, it offers a low compliance. On the other hand, the colonoscopy is an invasive technique wherein the most severe complication generally is the gastrointestinal perforation. Moreover, colonoscopy is nowadays a procedure involving anesthesia, and the laxatives which are usually administered during the bowel preparation for colonoscopy are associated with several digestive problems.
It is important to note that the methods used today for screening general population at risk of suffering for CRC or AA are associated with a high rate of false positives. Consequently, a high amount of unnecessary follow-up colonoscopies is nowadays performed.
The present invention offers a clear solution to the problems cited above because it is focused on an in vitro method for identifying or screening human subjects at risk of suffering from colorectal cancer or colorectal adenomas (particularly advanced colorectal adenomas), departing from the concentration level of protein biomarkers isolated from minimally-invasive samples such as blood, serum or plasma. Since the method of the invention is based on blood, serum or plasma samples, it is expected to improve compliance to colorectal cancer screening. Moreover, the method of the invention offers high sensitivity and specificity, which means that it is a strong and cost-effective method for the detection of both colorectal cancer and colorectal adenomas.
The present invention refers to an in vitro method for screening general population for colorectal cancer and/or advanced colorectal adenomas, departing from the concentration level of protein biomarkers isolated from minimally-invasive samples such as blood, serum or plasma. The method of the invention offers high sensitivity and specificity, which means that it is a strong and cost-effective method for the detection of both colorectal cancer and colorectal adenomas.
Since the method of the invention has higher sensitivity and specificity as compared to the method used today (FIT) for screening general population at risk of suffering from CRC or AA, it is associated with a lower percentage of false positives. Consequently, the method described in the present invention clearly helps in reducing the number of follow-up colonoscopies, thus improving the way that the patients are nowadays screened. Once the method of the invention is performed, if it is determined that the patients might be suffering from colorectal cancer and/or precancerous stage, the result is confirmed by colonoscopy. However, if it is not determined that the patient might be suffering from colorectal cancer and/or precancerous stage, there is no need to perform a colonoscopy and routine testing with the method of the invention defined below is recommended.
Particularly, the first embodiment of the present invention refers to an in vitro method (hereinafter “method of the invention”) for screening general population for colorectal cancer and/or a pre-cancerous stage thereof which comprises: a) Measuring the concentration level of at least TFF3, in a minimally invasive biological sample obtained from the subject, and b) wherein if a deviation or variation of the concentration level is identified, as compared with the reference concentration level measured in healthy control subjects, this is indicative that the subject is suffering from colorectal cancer or a precancerous stage thereof.
Alternatively, the first embodiment of the present invention refers to an in vitro method for detecting at least TFF3 in a test sample from a asymptomatic human subject at risk of developing colorectal cancer and/or a pre-cancerous stage thereof, comprising: detecting whether the protein biomarker is present in a minimally invasive sample obtained from the subject by contacting the plasma sample with an antibody directed against said protein biomarker and detecting binding between the protein and the antibody.
In a preferred embodiment, the present invention refers to an in vitro method for screening general population for colorectal cancer and/or a pre-cancerous stage thereof which comprises: a) Measuring the concentration level of at least the combination [TFF3 and Flt3L], in a minimally invasive biological sample obtained from the subject, and b) wherein if a deviation or variation of the concentration level of at least the combination [TFF3 and Flt3L] is identified, as compared with the reference concentration level measured in healthy control subjects, this is indicative that the subject is suffering from colorectal cancer or a precancerous stage thereof.
In this regard, it is important to consider that the most reliable biomarker identified in the present invention for screening general population for colorectal cancer or a precancerous stage thereof is TFF3 (see Table 3). Moreover, the present invention also offers signatures for CRC screening always comprising TFF3 or [TFF3 and Flt3L] which show an AUC>0.8), for example: [TFF3 and Flt3L and HGFR], [TFF3 and Flt3L and IGFBP2], [TFF3 and Flt3L and CD147], [TFF3 and Flt3L and CD163], [TFF3 and Flt3L and CYFRA21-1], [TFF3 and Flt3L and HGFR and IGFBP2], [TFF3 and Flt3L and HGFR and CD147], [TFF3 and Flt3L and IGFBP2 and CD147], [TFF3 and Flt3L and CD163 and IGFBP2], [TFF3 and Flt3L and CD163 and HGFR], [TFF3 and Flt3L and CD163 and CD147], [TFF3 and Flt3L and CYFRA21-1 and CD147], [TFF3 and Flt3L and CYFRA21-1 and IGFBP2], [TFF3 and Flt3L and CD163 and CYFRA21-1], [TFF3 and Flt3L and HGFR and CYFRA21-1]. Consequently, any of the signatures comprising TFF3 or [TFF3 and Flt3L] could be effectively used according to the present invention, since they offer an AUC value above 0.8 for CRC screening and a good performance for of AA screening.
In a particularly preferred embodiment, the method of the invention comprises a) measuring the concentration level of at least the combination [TFF3 and Flt3L and HGFR], [TFF3 and Flt3L and IGFBP2], [TFF3 and Flt3L and CD147], [TFF3 and Flt3L and CD163], [TFF3 and Flt3L and CYFRA21-1], [TFF3 and Flt3L and HGFR and IGFBP2], [TFF3 and Flt3L and HGFR and CD147], [TFF3 and Flt3L and IGFBP2 and CD147], [TFF3 and Flt3L and CD163 and IGFBP2], [TFF3 and Flt3L and CD163 and HGFR], [TFF3 and Flt3L and CD163 and CD147], [TFF3 and Flt3L and CYFRA21-1 and CD147], [TFF3 and Flt3L and CYFRA21-1 and IGFBP2], [TFF3 and Flt3L and CD163 and CYFRA21-1], [TFF3 and Flt3L and HGFR and CYFRA21-1], and b) wherein if a deviation or variation of the concentration level of at least one of the above cited combination of biomarkers is identified, as compared with the reference concentration level measured in healthy control subjects, this is indicative that the subject is suffering from colorectal cancer or a precancerous stage thereof. The second embodiment of the present invention refers to the in vitro use of any of the above cited biomarkers or signatures for screening general population for colorectal cancer or a precancerous stage thereof.
According to the method of the invention, after measuring the concentration level of any of the above cited combinations of biomarkers, a score value is obtained for the signature and this score value is compared with a threshold value which defines the diagnostic rule. If this score value is higher than the threshold, then the corresponding sample is classified as a positive sample, which is an indication that the patient might be suffering from colorectal cancer and/or pre-cancerous stage thereof. The threshold value has been defined in order to optimize sensitivity and specificity values. Consequently, in a preferred embodiment, the method of the invention comprises: a) Measuring the concentration level of any of the above cited combinations of biomarkers, in a biological sample obtained from the subject, b) processing the concentration values in order to obtain a risk score and c) wherein if a deviation or variation of the risk score value obtained for any of the above cited combinations of biomarkers is identified, as compared with a reference value, this is indicative that the subject is suffering from colorectal cancer and/or a pre-cancerous stage.
The third embodiment of the present invention refers to a kit of parts comprising reagents for determining the concentration level of any of the above cited biomarkers or signatures. In a preferred embodiment, the present invention refers to the in vitro use of a kit comprising reagents for the determination of the concentration level of any of the above cited biomarkers or signatures for screening general population for colorectal cancer or a precancerous stage thereof.
In a preferred embodiment, the pre-cancerous stage of colorectal cancer is advanced colorectal adenoma.
In a preferred embodiment, the method of the invention is confirmed by an image technique, preferably colonoscopy.
In a preferred embodiment the present invention refers to an in vitro method for screening general population for colorectal cancer or a precancerous stage thereof, said method comprising: a) obtaining a minimally invasive sample from a human patient; and b) detecting whether any of the above cited protein biomarkers or signatures are present in the sample by contacting the plasma sample with an antibody directed against said protein biomarkers or signatures and detecting binding between the proteins and the antibody.
The last embodiment of the present invention refers to a method for screening general population for colorectal cancer or a precancerous stage thereof and treating those subjects identified as suffering from colorectal cancer or a pre-cancerous stage thereof, which comprises: a) obtaining a minimally invasive sample from a human patient; b) detecting whether any of the above cited protein biomarkers or signatures are present in the sample; c) diagnosing the patient with colorectal cancer or a pre-cancerous stage thereof when the presence of said protein biomarkers or signatures in the sample is detected; and d) performing a colonoscopy to the patient and removing the colorectal cancer or polyps afterwards.
In a preferred embodiment, the present invention is a computer-implemented invention, wherein a processing unit (hardware) and a software are configured to:
For the purpose of the present invention the following terms are defined:
For the purpose of the present invention the following proteins are identified according to Uniprot data base:
X axis represents Specificity. Y axis represents Sensitivity.
The population of study was Spanish screening population. This means asymptomatic average risk subjects between age 50-75 referred to colonoscopy by a population screening program. Due to the low incidence of CRC in screening population, some CRC cases are patients already diagnosed with CRC that were scheduled for surgery (blood samples were obtained before colonoscopy or surgery resection). Subjects who have developed another type of cancer in the 5 years prior to their participation in the study or patients who have previously received chemotherapy or radiotherapy, or patients diagnosed with Non-Advanced Adenomas, Familiar Adenomatous Polyposis or Lynch Syndrome, Inflammatory Bowel Disease, or inadequate intestinal preparation for colonoscopy or subjects who have undergone colonoscopy/polypectomy in the previous 5 years were excluded from the study.
At the end, a total of 180 subjects from six Spanish hospitals (Hospital de Burgos, Hospital de Vigo, Hospital de Alicante, Hospital de Ourense, Instituto Valenciano de Oncologia, and Hospital de Bellvitge) were prospectively included in this study: 120 patients newly diagnosed with sporadic colorectal neoplasia (60 with CRC and 60 with AA) and 60 healthy individuals.
The results were validated in a cohort of 92 subjects from four Spanish hospitals (Hospital de Burgos, Hospital de Vigo, Hospital de Ourense, Instituto Valenciano de Oncologia): 59 patients diagnosed with sporadic colorectal neoplasia (32 with CRC and 27 with AA) and 33 healthy individuals.
All subjects without personal history of any cancer and with a recent colonoscopy confirming the lack of colorectal neoplastic lesions. Patients with AA were those with adenomas having a size of at least 10 mm or histologically having high grade dysplasia or >20% villous component. The characteristics of participants are shown in Table 1 and Table 2. Blood samples were collected prior to endoscopy or surgery in all individuals.
The study was approved by the Institutional Ethics Committee of each Hospital, and written informed consent was obtained from all participants in accordance with the Declaration of Helsinki.
Ten mL of whole blood from each participant were collected in EDTA K2 containing tubes. Blood samples were placed at 4° C. until plasma separation. Samples were centrifuged at 1,600×g for 10 min at 4° C. to spin down blood cells, and plasma was transferred into new tubes, followed by further centrifugation at 16,000×g for 10 minutes at 4° C. to completely remove cellular components.
Blood samples were obtained before colonoscopy or surgery resection.
The concentration of the biomarkers in plasma samples was established using commercial ELISA (Enzyme-linked immunosorbent assay) and CLIA (Chemiluminescence immunoassay) test and following their corresponding instruction manual. HGFR, ErbB4, CEA, CD163, DKK3, IGFBP2, and TFF3 was analyzed with ELISA kit from Cloud clone Corp. Level of CD147, Flt3L, FasL and Casp4, was measured using ELISA Kit form Elabscience. In the case of the DCSINGR, ELISA kit from RayBio was used. PKM2 were analyzed with ELISA kit from Aviva and ADAMDEC1 with ELISA kit from Cusabio. Related to CLIA test, CYFRA21-1 y AREG was analyzed with CLIA test from Cloud Clone Corp.
For the protein quantification step the samples were processed with the corresponding kit (ELISA/CLIA) and distributed in experimental plates. Each plate contained also control data used to construct a standard curve. Fluorescence data obtained from each run (expressed as integer numbers) have been background corrected for each sample and quantified using a standard curve generated using a 2-degree polynomial regression model.
Three groups of individuals were considered in the analysis. CRC (Individuals diagnosed with colorectal cancer), AA (Individuals diagnosed with advanced adenoma) and CTL (Individuals with no disease).
Raw quantification data have been transformed by applying square root function, and then centering and scaling so that, after the transformation, each protein measure has mean 0 and standard deviation 1.
To deal with non-normality issues, Wilcoxon rank-sum test was used to compare either CRC cases or AA cases against CTL individuals.
Diagnostic performance for the individual proteins and some of their combinations has been assessed by their receiver operating characteristic (ROC) curves, and the area under the ROC curves (AUC). Moreover, sensitivities, specificities, positive predictive and negative predictive values (PPV and NPV) for the different tests were calculated at the optimal cutoff point defined by the best Youden's Index (or equivalently, the point of the ROC that maximizes the sum of sensitivity and specificity).
Scores used for deriving the ROC-AUCs and the rest of performance values were obtained using univariate logistic regression model for the individual proteins and multivariate logistic regression models for the different combination of proteins considered. 95% CI for the AUCs was obtained with the DeLong methodology both in individual markers and combination of them.
All the individual performance metrics obtained from the previous analysis are summarized in Table 3 and Table 4.
Moreover, multivariate analysis has been carried out to explore if combinations of proteins improve the performance of individual markers. We have used multivariate logistic regression to fit models with all possible combinations of two, three and four proteins.
Different metrics to evaluate the individual proteins were determined, also perming the following comparisons: CRC/AA vs CTL. Table 3 and Table 4 show these metrics for individual proteins, including p-value from Wilcoxon test (p.Wilc), area under the ROC curve (AUC), and Sensitivity (Sens.) and Specificity (Spec.) values, computed in the cut-off point of the ROC curve with the best Youden's index.
It can be seen that TFF3, CYFRA21-1, Flt3L and AREG are significantly (p<0.05) different between CRC and CTL groups and their AUC are significantly different from 0.5 (as their 95% confidence interval do not include 0.5). In the case of AA group, CASP4 and CYFRA21-1 also shows statistically differences compared to CTL group.
Additionally, there are statistical significances between early stage vs control (p value=0.00098), and early stage+AA vs control (p value=0.0048) indicating that TFF3 is a good marker for screening purposes (i.e. early detection).
With the aim of improving individual diagnostic capability, combinations of proteins have been explored. All possible combinations of two, three and four proteins have been analyzed.
We have used the cohort of 180 subjects for developing models with all possible combinations and we have used the validation cohort (n=92) to obtain validated performance metrics (AUC values, Sens, Spec, PPV and NPV).
Table 5, Table 6 and Table 7 show the AUC achieved for the combinations of two, three and four biomarkers respectively, discriminating CRC from CTL.
Since the TFF3/Flt3L pair appears as the best combination of two proteins and it is also present among the top combinations of three and four markers in the CRC. vs. CTL comparison, we have explored its performance in discriminating AA from CTL.
We obtained an AUC of 0.5361 when using the pair TFF3/Flt3L for discriminating AA from CTL. We combined this pair with the rest of proteins to obtain combinations of three and four markers. Table 8 and Table 9 shows the AUC achieved for these combinations of three and four biomarkers respectively, discriminating AA vs CTL.
Based on their respective AUCs, the best models have been selected. Table 10 shows the best results for CRC and Table 11 shows the best results for AA. The metrics for the best combinations of proteins are included, comprising area under the ROC curve (AUC), Sensitivity (Sens.), Specificity (Spec.), and positive (PPV) and negative (NPV) predictive values computed in the cut-off point of the ROC curve with the best Youden's index.
Table 12 has been designed to show the overlapping of the most important signatures claimed in the present invention for CRC. It is clearly shown that most of the best signatures comprise [TFF3 and Flt3L]
Table 13 has been designed to show the overlapping of the most important signatures claimed in the present invention for AA. It is clearly shown that [TFF3 and CYFRA21-1] is also included in combination of biomarkers showing a good performance for AA.
| Number | Date | Country | Kind |
|---|---|---|---|
| 20382204.4 | Mar 2020 | EP | regional |
| 20382205.1 | Mar 2020 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2021/056984 | 3/18/2021 | WO |
